Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal

02:29 PM EDT, 08/26/2026 (MT Newswires) -- (Updates with the company's stock move in the headline and the first paragraph.) Biuohaven (BHVN) shares were up more than 23% in Wednesday trading after the company signed a licensing and collaboration agreement with SK Biopharmaceuticals for an investigational focal epilepsy treatment. SK Biopharmaceuticals will gain exclusive global rights to the treatment and take over all future program costs, the companies said. The agreement includes $350 million payable at closing and a $50 million payment due in 2027, along with $150 million in potential regulatory milestones, alongside tiered royalties on net sales. The acquiring partner will assume $245 million in specific financial obligations tied to the drug platform. Price: 17.77, Change: +3.39, Percent Change: +23.60